LPL Financial LLC cut its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 8.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,899 shares of the company’s stock after selling 3,704 shares during the quarter. LPL Financial LLC owned about 0.87% of VanEck Pharmaceutical ETF worth $3,222,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in PPH. Raymond James & Associates grew its holdings in VanEck Pharmaceutical ETF by 11.1% in the 1st quarter. Raymond James & Associates now owns 11,431 shares of the company’s stock valued at $912,000 after buying an additional 1,144 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in VanEck Pharmaceutical ETF by 5.1% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 3,471 shares of the company’s stock valued at $277,000 after buying an additional 167 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in shares of VanEck Pharmaceutical ETF by 55.6% during the 1st quarter. Vontobel Holding Ltd. now owns 17,500 shares of the company’s stock worth $1,396,000 after purchasing an additional 6,250 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of VanEck Pharmaceutical ETF by 5.6% during the 1st quarter. Cetera Investment Advisers now owns 2,808 shares of the company’s stock worth $224,000 after purchasing an additional 150 shares in the last quarter. Finally, Equitable Holdings Inc. acquired a new stake in shares of VanEck Pharmaceutical ETF during the 1st quarter worth $238,000.
VanEck Pharmaceutical ETF Stock Performance
PPH opened at $77.28 on Wednesday. The firm has a market cap of $393.36 million, a P/E ratio of 16.59 and a beta of 0.72. VanEck Pharmaceutical ETF has a 52-week low of $71.70 and a 52-week high of $83.35. The business’s fifty day moving average is $79.59 and its 200-day moving average is $79.14.
VanEck Pharmaceutical ETF Dividend Announcement
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
- Five stocks we like better than VanEck Pharmaceutical ETF
- Your Comprehensive Guide to Investing in Bank Stocks
- GSK is a remedy for the winter investment blahs
- How to Invest in Toy Stocks
- After blowout earnings, Integer may be headed to new highs
- How to Capture the Benefits of Dividend Increases
- Banking and trucking: Is the economy rolling toward troubles?
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.